↓ Skip to main content

Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer

Overview of attention for article published in Radiation Oncology, February 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
Published in
Radiation Oncology, February 2017
DOI 10.1186/s13014-016-0741-4
Pubmed ID
Authors

Jun-ichi Saitoh, Katsuyuki Shirai, Masumi Imaeda, Atsushi Musha, Takanori Abe, Masato Shino, Yukihiro Takayasu, Katsumasa Takahashi, Kazuaki Chikamatsu, Takashi Nakano

Abstract

To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer. Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m(2), five times a week), plus weekly DTX (10 mg/m(2)) for up to 4 weeks from the commencement of RT. Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient. CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control. UMIN000025046 . Registered 1 October 2015, retrospectively registered.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 20%
Student > Master 3 15%
Researcher 3 15%
Professor > Associate Professor 2 10%
Student > Ph. D. Student 2 10%
Other 3 15%
Unknown 3 15%
Readers by discipline Count As %
Medicine and Dentistry 11 55%
Nursing and Health Professions 2 10%
Biochemistry, Genetics and Molecular Biology 1 5%
Immunology and Microbiology 1 5%
Engineering 1 5%
Other 0 0%
Unknown 4 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2018.
All research outputs
#18,627,279
of 23,075,872 outputs
Outputs from Radiation Oncology
#1,429
of 2,074 outputs
Outputs of similar age
#237,812
of 310,448 outputs
Outputs of similar age from Radiation Oncology
#16
of 26 outputs
Altmetric has tracked 23,075,872 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,074 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,448 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.